Early-onset peak dose Levodopa induced dyskinesia in elderly Ethiopian Parkinson’s disease patient
Objective: The aim was to report an early onset peak dose dyskinesia in a 55 years old Parkinson's disease patient who was naive to treatment…Safety and efficacy of istradefylline, an adenosine A2A receptor antagonist, as a function of baseline dyskinesia (BL-dyskinesia) in Parkinson’s disease (PD): A pooled analysis of 4 studies
Objective: To evaluate the effect of BL-dyskinesia on the efficacy and safety of istradefylline in 4 randomized, placebo-controlled, double-blind, phase 2b/3 trials. Background: Istradefylline, a…MDS Translation Program for MDS-UPDRS, UDysRS, and MDS-NMS
Objective: To summarize the status of the ongoing MDS-sponsored translation programs for non-English versions of the MDS-UPDRS, UDysRS, and MDS-NMS. Background: The MDS-UPDRS, UDysRS, and…Movement Disorders in the Plain People
Objective: Genomic discovery often occurs in large institutions, but the contribution of small, rural genetics clinics must not be overlooked. While rare, these rural genetics…The Levodopa in Early Parkinson’s disease (LEAP) study: Post-hoc analyses
Objective: We present the results of several post hoc analyses of the LEAP-study. Background: Among patients with Parkinson’s disease who were evaluated in the LEAP-study…Long-term effect of deep brain stimulation in a monkey model of Parkinson’s disease with L-Dopa–induced dyskinesias
Objective: This study investigated the effect of long-term deep brain stimulation (DBS) of the subthalamic nucleus (STN) on motor behavior in a parkinsonian monkey treated…4-Chlorokynurenine inhibits L-Dopa-induced dyskinesias in non-human parkinsonian primates
Objective: This study investigated the antidyskinetic activity of 4-chlorokynurenine (AV-101) in parkinsonian monkeys with L-Dopa-induced dyskinesias. Background: The common treatment for Parkinson’s disease (PD) is L-Dopa…Pridopidine for the treatment of Levodopa-induced Dyskinesia in patients with Parkinson’s disease
Objective: To assess the efficacy and safety of pridopidine in PD patients with Levodopa-induced dyskinesia (LID). Background: Pridopidine is a small molecule in clinical development…The Subthalamic Fasciculus and Connectivity Profiling of Stimulation-induced Dyskinesia following Pallidal DBS in Parkinson’s Disease
Objective: To identify anatomical regions related to stimulation-induced dyskinesia (SID) following pallidal deep brain stimulation (DBS) in Parkinson’s disease (PD) and to analyze structural and…The study of the role of genetic risk factors in levodopa-induced dyskinesia development in Russian patients with Parkinson’s disease: a pilot study
Objective: The aim of our study is to search for genetic risk factors for the development of motor side effects of dopaminergic therapy, such as…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 44
- Next Page »